Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription

EMBO Journal

Volumn 26, Issue 7, 2007, Pages 1878-1890

  Casalino, Laura ^a,b   Bakiri, Latifa ^c   Talotta, Francesco ^a   Weitzman, Jonathan B ^b   Fusco, Alfredo ^d   Yaniv, Moshe ^b   Verde, Pasquale ^a  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b INSTITUT PASTEUR   (France)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

AP 1; Cyclin A; Fra 1; RAS transformation; Thyroid

Indexed keywords

CYCLIN A; CYCLIN A2; RAS PROTEIN; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ANAPHASE; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL DIVISION; CELL FRACTIONATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC LINKAGE; GENETIC TRANSCRIPTION; GENETIC TRANSFORMATION; GENOMIC INSTABILITY; MICRONUCLEUS; MITOSIS; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RAT; THYROID CELL; THYROID TUMOR;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL SURVIVAL; CLONE CELLS; CYCLIN A; FLOW CYTOMETRY; G2 PHASE; GENES, RAS; MITOSIS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RNA INTERFERENCE; THYROID GLAND; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC;

RATTUS;

EID: 34247198505     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7601617     Document Type: Article

References (45)

1. Andersen H, Mejlvang J, Mahmood S, Gromova I, Gromov P, Lukanidin E, Kriajevska M, Mellon JK, Tulchinsky E (2005) Immediate and delayed effects of e-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells. Mol Cell Biol 25: 9138-9150
2. Andrecht S, Kolbus A, Hartenstein B, Angel P, Schorpp-Kistner M (2002) Cell cycle promoting activity of JunB through cyclin A activation. J Biol Chem 277: 35961-35968
3. Avvedimento VE, Musti AM, Ueffing M, Obici S, Gallo A, Sanchez M, DeBrasi D, Gottesman ME (1991) Reversible inhibition of a thyroid-specific trans-acting factor by Ras. Genes Dev 5: 22-28
4. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M (2000) Cell cycledependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 19: 2056-2068
5. Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M (2002) Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol 22: 4952-4964
6. Beier F, Taylor AC, LuValle P (2000) Activating transcription factor 2 is necessary for maximal activity and serum induction of the cyclin A promoter in chondrocytes. J Biol Chem 275: 12948-12953
7. Belguise K, Kersual N, Galtier F, Chalbos D (2005) FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24: 1434-1444
8. Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, Pestell RG, Greenberg ME (1998) Fos family members induce cell cycle entry by activating cyclin D1. Mol Cell Biol 18: 5609-5619
9. Burch PM, Yuan Z, Loonen A, Heintz NH (2004) An extracellular signal-regulated kinase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry. Mol Cell Biol 24: 4696-4709
10. Casalino L, De Cesare D, Verde P (2003) Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol 23: 4401-4415
11. Coverley D, Laman H, Laskey RA (2002) Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat Cell Biol 4: 523-528
12. Debinski W, Gibo DM (2005) Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 3: 237-249
13. Eferl R, Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868
14. Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, Amling M, Wagner EF (2004) The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 23: 2789-2799
15. Francis-Lang H, Zannini M, De Felice M, Berlingieri MT, Fusco A, Di Lauro R (1992) Multiple mechanisms of interference between transformation and differentiation in thyroid cells. Mol Cell Biol 12: 5793-5800
16. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G (1987) One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 7: 3365-3370
17. Guadagno TM, Ohtsubo M, Roberts JM, Assoian RK (1993) A link between cyclin A expression and adhesion-dependent cell cycle progression. Science 262: 1572-1575
18. Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973
19. Jochum W, David JP, Elliott C, Wutz A, Plenk Jr H, Matsuo K, Wagner EF (2000) Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6: 980-984
20. Kang JS, Krauss RS (1996) Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. Mol Cell Biol 16: 3370-3380
21. Katabami M, Donninger H, Hommura F, Leaner VD, Kinoshita I, Chick JF, Birrer MJ (2005) Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells. J Biol Chem 280: 16728-16738
22. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457
23. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP (2001) Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22: 631-656
24. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18: 7095-7105
25. Lallemand D, Spyrou G, Yaniv M, Pfarr CM (1997) Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogene 14: 819-830
26. Mailand N, Diffley JF (2005) CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122: 915-926
27. Mechta F, Lallemand D, Pfarr CM, Yaniv M (1997) Transformation by ras modifies AP1 composition and activity. Oncogene 14: 837-847
28. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M (2005) The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068-1081
29. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA (1999) Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol 1: 88-93
30. Milde-Langosch K (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41: 2449-2461
31. Missero C, Pirro MT, Di Lauro R (2000) Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1. Mol Cell Biol 20: 2783-2793
32. Newman JR, Keating AE (2003) Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science 300: 2097-2101
33. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G (1992) Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971
34. Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65: 1244-1250
35. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA (2000) The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19: 3948-3954
36. Schreiber M, Wang ZQ, Jochum W, Fetka I, Elliott C, Wagner EF (2000) Placental vascularisation requires the AP-1 component fra1. Development 127: 4937-4948
37. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136
38. Shimizu M, Nomura Y, Suzuki H, Ichikawa E, Takeuchi A, Suzuki M, Nakamura T, Nakajima T, Oda K (1998) Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4. Exp Cell Res 239: 93-103
39. Sunters A, Thomas DP, Yeudall WA, Grigoriadis AE (2004) Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity. J Biol Chem 279: 9882-9891
40. Sylvester AM, Chen D, Krasinski K, Andres V (1998) Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation. J Clin Invest 101: 940-948
41. Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, Viglietto G, Fusco A, Verde P (1997) Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 16: 5310-5321
42. Vial E, Marshall CJ (2003) Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J Cell Sci 116: 4957-4963
43. Vial E, Sahai E, Marshall CJ (2003) ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4: 67-79
44. Yam CH, Fung TK, Poon RY (2002) Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326
45. Yoshizumi M, Wang H, Hsieh CM, Sibinga NE, Perrella MA, Lee ME (1997) Down-regulation of the cyclin A promoter by transforming growth factor-beta1 is associated with a reduction in phosphorylated activating transcription factor-1 and cyclic AMP-responsive element-binding protein. J Biol Chem 272: 22259-22264